{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MATCHING+PLACEBO&page=7", "query": { "intervention": "MATCHING PLACEBO", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 7024, "total_pages": 703, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MATCHING+PLACEBO&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MATCHING+PLACEBO&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T02:59:17.203Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00655642", "title": "Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Nausea" ], "interventions": [ { "name": "Ondansetron", "type": "DRUG" }, { "name": "Metoclopramide", "type": "DRUG" }, { "name": "Promethazine", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2007-03", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2013-10-30", "last_synced_at": "2026-10-28T02:59:17.203Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655642" }, { "nct_id": "NCT02422186", "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Treatment-Resistant" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral Antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (New Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 139, "start_date": "2015-08-20", "completion_date": "2017-08-10", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-28T02:59:17.203Z", "location_count": 15, "location_summary": "San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02422186" }, { "nct_id": "NCT05819866", "title": "A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cerebral Adrenoleukodystrophy (cALD)" ], "interventions": [ { "name": "Leriglitazone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Minoryx Therapeutics, S.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2023-07-12", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-28T02:59:17.203Z", "location_count": 4, "location_summary": "Palo Alto, California • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneota", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05819866" }, { "nct_id": "NCT02439320", "title": "Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Migraine" ], "interventions": [ { "name": "Lasmiditan 100 mg", "type": "DRUG" }, { "name": "Lasmiditan 200 mg", "type": "DRUG" }, { "name": "Placebo (matches lasmiditan doses)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2231, "start_date": "2015-04", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2019-12-16", "last_synced_at": "2026-10-28T02:59:17.203Z", "location_count": 92, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Fountain Hills, Arizona + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02439320" }, { "nct_id": "NCT01609582", "title": "Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes", "Cardiovascular Disease" ], "interventions": [ { "name": "TAK-875", "type": "DRUG" }, { "name": "TAK-875 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3207, "start_date": "2012-06", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-10-19", "last_synced_at": "2026-10-28T02:59:17.203Z", "location_count": 218, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01609582" }, { "nct_id": "NCT01437046", "title": "Doxazosin an a1 Antagonist for Alcohol Dependence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Alcohol Dependence", "Anxiety" ], "interventions": [ { "name": "Doxazosin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 41, "start_date": "2011-11-01", "completion_date": "2015-03-01", "has_results": false, "last_update_posted_date": "2025-08-18", "last_synced_at": "2026-10-28T02:59:17.203Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01437046" }, { "nct_id": "NCT07672769", "title": "Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Higher Risk Myelodysplastic Syndromes" ], "interventions": [ { "name": "bexmarilimab (1mg/kg)", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "bexmarilimab (3mg/kg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Faron Pharmaceuticals Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2026-10", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-28T02:59:17.203Z", "location_count": 9, "location_summary": "Duarte, California • Aurora, Colorado • New Haven, Connecticut + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07672769" }, { "nct_id": "NCT07837973", "title": "Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Overweight , Obesity", "Adults" ], "interventions": [ { "name": "ALV-100", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alveus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 220, "start_date": "2026-08-10", "completion_date": "2027-08-24", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-28T02:59:17.203Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07837973" }, { "nct_id": "NCT05771675", "title": "Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Recurrent Acute Pancreatitis", "Chronic Pancreatitis" ], "interventions": [ { "name": "Simvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2024-10-24", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-28T02:59:17.203Z", "location_count": 5, "location_summary": "Los Angeles, California • Stanford, California • Columbus, Ohio + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05771675" }, { "nct_id": "NCT01289912", "title": "Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tuberous Sclerosis Complex" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mustafa Sahin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Years to 21 Years" }, "enrollment_count": 52, "start_date": "2011-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2018-01-25", "last_synced_at": "2026-10-28T02:59:17.203Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Cincinnati, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289912" } ] }